Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:34 PM
Ignite Modification Date:
2025-12-24 @ 2:34 PM
NCT ID:
NCT07233759
Eligibility Criteria:
Inclusion Criteria:
* Hepatocellular carcinoma participants who received treatment at National Taiwan University Hospital between January 1, 2019, and June 30, 2026, and had used the following medications.
1. Pembrolizumab /keytruda
2. Atezolizumab / Tecentriq
3. Nivolumab
4. Lenvatinib
5. Stivarga
Exclusion Criteria:
* None
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT07233759
Study Brief:
Protocol Section:
NCT07233759